Panacea Life Sciences Holdings, Inc. Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
Panacea Life Sciences Holdings, Inc. (PLSH) reported Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net of -$1.64 million for the 3-month period ending 2021-03-31, per its 10-Q/A filed 2021-05-27.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net
us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet · last filed 2021-05-27
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2021-03-31 was -$1.64M.
- Panacea Life Sciences Holdings, Inc. fair value, net derivative asset (liability) measured on recurring basis, unobservable inputs reconciliation, transfers, net for the quarter ending 2020-09-30 was -$74.16K.
| Period end | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 3 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 6 month | Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Transfers, Net 9 month |
|---|---|---|---|
| 2021-03-31 | -$1.64M 10-Q/A · filed 2021-05-27 | ||
| 2020-09-30 | -$74.16K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-18 | -$129.71K 10-Q · filed 2020-11-18 | |
| 2020-06-30 | -$55.55K 10-Q · filed 2020-08-19 |